Scandion Oncology (Scandion) will publish its Q1 2022 interim report on Thursday, May 19, 2022 before 09:00 CET.
Scandion Oncology’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
Access to the event can be obtained as follows:
LIVE access on Thursday May 19, 2022 at 10:00 CET
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
The information was provided by the contact person above for publication on May 16, 2022, at 08.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at firstname.lastname@example.org or +46 (0) 40 200 250.